Epiminder has signed a five-year rolling partnership with Stratus Neuro to integrate its long-term Minder EEG data into StratusEEG, a cloud platform used by more than 7,000 US clinicians and administrators. The agreement gives Epiminder an established clinical workflow for its DETECT study and planned US commercialisation, although no financial terms or launch date were disclosed.
dorsaVi has inked a five-year sales agreement with Select Medical, opening access to over 1,900 US outpatient physical therapy centers for its FDA-approved motion analysis products. This follows a successful 18-month pilot validating clinical benefits in athlete rehabilitation.